Beruflich Dokumente
Kultur Dokumente
Medication Administration
Vol. 16 Issue 9
September 2015
Indications
Zohydro ER and Hysingla ER are indicated
for the treatment of chronic pain that requires
daily, around-the-clock, long-term therapy. They
are used only when other treatments have not
been adequate or tolerated, and are not
indicated for intermittent (as-needed or prn) use.
Pharmacodynamics
Like other opioids, these drugs reduce pain
by binding to specific receptors in the brain and
spinal cord involved in the transmission of pain
impulses.
Pharmacokinetics
Absorption: Well-absorbed from the GI tract;
may be taken without regard to meals
Distribution: Extensively distributed throughout
body tissues; low protein binding
Metabolism: Metabolized in the liver, primarily
via the CYP3A4 enzymes
Elimination: Excreted via the kidneys
Major Interactions
Alcohol: Use of alcohol with extendedrelease forms of opioids, such as Zohydro ER
and Hysingla ER, may cause rapid release of
the opioid. This can raise serum drug levels to
dangerous, and possibly fatal, levels. As a CNS
depressant, alcohol use also increases the risk
of severe respiratory depression.
CNS depressants, such as sedatives,
hypnotics and other opioids: Increased risk of
severe respiratory depression.
Ketoconazole, erythromycin and ritonavir,
among others (CYP3A4 inhibitors): May
significantly increase opioid drug levels.
Rifampin, phenytoin and carbamazepine
(CYP3A4 inducers): Stopping these drugs during
use of Zohydro ER or Hysingla ER may cause
significant increase in opioid drug levels. Starting
these drugs during the opioid treatment may
cause a decrease in serum opioid levels, and
may precipitate withdrawal.
Page 2
Vol. 16 Issue 9
September 2015
DATE:
UNIT:
Directions: Place the letter of the one best answer in the space provided.
_____1. Zohydro ER is indicated for:
A. daily, 24-hour treatment of pain
B. acute and chronic pain, lasting days to months
C. intermittent use, taken as needed for pain
D. all of the above
_____2. A major difference between Zohydro ER and Hysingla ER is that:
A. Hysingla ER is a long-acting, single-entity hydrocodone; Zohydro ER is not
B. Zohydro ER has abuse-deterrent technology, while Hysingla ER does not
C. Hysgingla ER is taken once daily, while Zohydro ER is taken every 12 hours
D. Zohydro ER contains acetaminophen; Hysingla ER does not
_____3. There is little to no risk of respiratory depression when long-acting hydrocodone is
administered by the oral route.
A. True
B. False
_____4. A patient who began taking Zohydro ER two days ago states that he feels light-headed
and dizzy when the nurse helps him get out of bed and walk to the bathroom. Which
adverse effect of Zohydro ER is he most likely experiencing?
A. urinary retention
B. physical drug dependence
C. headache
D. orthostatic hypotension
_____5. The use of Zohydro ER is contraindicated for which of the following patients:
A. Mr. N, who has severe asthma
B. Mrs. D, who has a history of substance abuse
C. Mr. Y, who is 82 years old
D. Mrs. V, who is currently taking erythromycin
_____6. A patient who is taking Zohydro ER has become unable to swallow, and a feeding tube has
been inserted. The appropriate nursing action in this situation is to:
A. administer the previously-ordered prn opioid whenever the patient has pain
B. open the Zohydro ER capsule and mix the beads with water to put down the tube
C. call the prescriber to request a different pain medication
D. call the prescriber to obtain orders for the IV form of Zohydro ER
_____7. When starting Hysingla ER, the greatest risk of adverse effects occurs within the first:
A. two hours
B. three days
C. two weeks
D. month
_____8. Other opioid pain medications should never be administered to a patient currently taking
Zohydro ER or Hysingla ER.
A. True
B. False
_____9. When administering Zohydro ER or Hysingla ER, increased frequency of assessment and
monitoring is required for patients with:
A. emphysema
B. renal impairment
C. a history of seizures
D. all of the above
_____10. A patient taking Zohydro ER makes all of the following statements. Which one carries the
greatest risk of harm to the patient:
A. After I take it in the morning, I dont eat breakfast. Ill eat something around noon.
B. Theyre big pills, but I make sure to swallow them whole.
C. Im able to drive without any problems.
D. I occasionally have a martini or two in the evening.
Page 2
Unit
Test Date
Score
Additional Information:
Phone: (804) 233-3707
Fax:
(804) 233-3705
Email: editor@peakdev.com
1. Issue:
Month:
2. Facility Information
(provide information about the subscribing facility):
Facility Name: ________________________________
Address: ___________________________________
___________________________________
City: _________________ State: _____ Zip: _______
3. Applicant Information
(provide information about yourself)
Name: ___________________________________
Address: _________________________________
City: ________________ State: _____ Zip: ______
Daytime Phone Number:___________________
Nursing License #: ________________________
Licensing State: __________________________
Previous Peak Development Contact Hours: Yes
No
6. PAYMENT INFORMATION:
APPLICATIONS MUST INCLUDE PAYMENT
Cost: $10 per test nonrefundable
Check Payment method - Provide all information
_______ Check Payable to Peak Development Resources
($40.00 service fee for returned checks)
_______ Credit Card (circle one):
VISA
MASTERCARD
Credit Card Number: ____________________________
Credit Card Expiration Date: ___________
Print Name on Card: ____________________________
Authorized Signature: ___________________________
Billing Address for credit card:
Address: _______________ _____________________
____________________________________
State: ________ Zip: __________
7. EVALUATION
A. How long, in minutes, did it take you to complete
this educational packet? _______minutes.
B.
1.
2.
3.
4.
5.
6.
7.
8.
9.